India is taking a major step toward combating dengue, one of the country’s most persistent public health challenges. A Phase III clinical trial is currently underway for DengiAll, a single-dose dengue vaccine developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR).

This trial is seen as a milestone in the fight against dengue, especially since India currently has no licensed dengue vaccine or antiviral treatment. With the trial progressing steadily, participant enrollment is expected to be completed by October 2025, and the results could be published in 2026.

🧪 What is DengiAll?

DengiAll is a one-shot vaccine designed to protect against all four serotypes of the dengue virus — a crucial feature since multiple dengue infections increase the risk of severe disease. The vaccine is based on a strain originally developed by the National Institutes of Health (NIH), USA.

Its goal? To provide long-term immunity, reduce the disease burden, and prevent hospitalizations, especially in children and vulnerable populations.

🔍 Key Highlights of the Clinical Trial

• Trial Phase: Currently in Phase III
• Type: Multi-center, double-blind, randomized, and placebo-controlled
• Participants: Approx. 10,500 participants across 20 trial sites in India
• Current Enrollment: Over 8,000 participants enrolled, expected to complete by October 2025
• Safety Status: No safety concerns reported from previous Phase I and II trials
• Target: All four dengue virus serotypes (DENV-1 to DENV-4)

🦠 Why Is This Vaccine So Important?

Dengue is a major public health threat in India, with frequent outbreaks and high hospital admissions. According to government data, over 12,000 cases were already reported by March 2024, with children being the most affected.

Key issues include:

• Lack of an existing vaccine or antiviral for dengue in India
• Multiple serotypes cause reinfection and severe illness
• Asymptomatic cases that spread unnoticed
• Increased burden on public health infrastructure

If successful, DengiAll could be India’s first approved dengue vaccine, offering a simple, one-dose solution to reduce the dengue burden.

⏳ When Will We Know the Results?

Since the trial is still ongoing, efficacy data is not yet available. The final results will likely be published in 2026, after all data is collected and analyzed post-October 2025.

The trial is focused on assessing:

• Vaccine efficacy in real-world conditions
• Long-term immunogenicity (how long immunity lasts)
• Safety and side effects, if any

👩‍⚕️ Why Doctors Should Stay Informed

As frontline healthcare professionals, doctors play a vital role in:

• Educating communities about dengue prevention and vaccination
• Participating in or referring patients for clinical research
• Supporting evidence-based immunization programs post-approval
• Addressing vaccine concerns with scientific clarity

Doctors can access more tools, updates, and discussions on vaccines and public health innovations at The Doctorpreneur Academy, a platform dedicated to empowering medical professionals with leadership, digital knowledge, and real-world healthcare insights.

🔗 Visit The Doctorpreneur Academy for updates on clinical trials, vaccine developments, and how to lead change in healthcare.

👉 To register for our next masterclass, please click here https://linktr.ee/docpreneur